0HS8:LSE:LSE-Caladrius Biosciences Inc. (USD)

COMMON STOCK | |

Last Closing

USD 3.8605

Change

0.00 (0.00)%

Market Cap

N/A

Volume

212.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-11 )

Largest Industry Peers for

Symbol Name Price(Change) Market Cap
0R2T:LSE Micron Technology Inc

N/A

USD 9,223,372,036.85B
0R2F:LSE Wells Fargo & Company

N/A

USD 9,223,372,036.85B
0R15:LSE SoftBank Group Corp.

N/A

USD 9,217.80B
0R1E:LSE Nintendo Co. Ltd.

N/A

USD 7,596.04B
0M69:LSE OTP Bank Nyrt

N/A

USD 5,014.80B
0R28:LSE Newmont Corp.

N/A

USD 4,231.43B
0R2O:LSE Freeport-McMoRan Inc.

N/A

USD 4,154.37B
0QY4:LSE Las Vegas Sands Corp.

N/A

USD 4,148.69B
0QYD:LSE Yum! Brands Inc.

N/A

USD 4,109.92B
0QZ4:LSE Delta Air Lines Inc.

N/A

USD 4,094.73B

ETFs Containing 0HS8:LSE

EATZ AdvisorShares Restaurant .. 5.43 % 0.00 %

N/A

USD 3.34M
HAU-U:CA 3.45 % 0.00 %

N/A

N/A
RCD Invesco S&P 500® Equal W.. 2.34 % 0.40 %

N/A

N/A
SDOG ALPS Sector Dividend Dogs.. 2.31 % 0.40 %

N/A

USD 1.18B
BTAL AGFiQ U.S. Market Neutral.. 0.45 % 0.00 %

N/A

N/A
RSP Invesco S&P 500® Equal W.. 0.23 % 0.20 %

N/A

N/A
XDEW:LSE Xtrackers S&P 500 Equal W.. 0.23 % 0.00 %

N/A

N/A
XDWE:LSE Xtrackers (IE) Public Lim.. 0.23 % 0.00 %

N/A

N/A
RXI iShares Global Consumer D.. 0.00 % 0.46 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification () Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 35.51% N/A N/A 100% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 35.51% N/A N/A 100% F
Trailing 12 Months  
Capital Gain 30.32% N/A N/A 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.32% N/A N/A 86% B+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 114.53% N/A N/A 95% A
Dividend Return 114.53% N/A N/A 95% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 207.84% N/A N/A 10% F
Risk Adjusted Return 55.10% N/A N/A 72% C
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike